{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:01:05Z","timestamp":1789909265345,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clim.2018.01.012","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T08:56:32Z","timestamp":1517561792000},"page":"60-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy"],"prefix":"10.1016","volume":"193","author":[{"given":"Ke","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yue","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Yu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Ren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2018.01.012_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clim.2018.01.012_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158390","article-title":"Welfare assessment following heterotopic or Orthotopic inoculation of bladder cancer in C57BL\/6 mice","volume":"11","author":"Miller","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2018.01.012_bb0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2018.01.012_bb0020","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.juro.2013.04.120","article-title":"Intravesical Gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","volume":"190","author":"Sternberg","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.clim.2018.01.012_bb0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000354085","article-title":"Larotaxel with Cisplatin in the first-line treatment of locally advanced\/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)","volume":"85","author":"Sternberg","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.clim.2018.01.012_bb0030","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.seminoncol.2012.08.007","article-title":"New therapeutic challenges in advanced bladder cancer","volume":"39","author":"Bellmunt","year":"2012","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.clim.2018.01.012_bb0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrurol.2016.121","article-title":"Cisplatin response is modulated by AR activity","volume":"13","author":"cancer","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.clim.2018.01.012_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2018.01.012_bb0045","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.urolonc.2016.10.017","article-title":"Emerging role of immunotherapy in urothelial carcinoma-Advanced disease","volume":"34","author":"Zibelman","year":"2016","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.clim.2018.01.012_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-derived suppressor cells critical cells driving immune suppression in the tumor microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0055","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fimmu.2015.00523","article-title":"Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate","volume":"6","author":"Meirow","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2018.01.012_bb0060","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.1158\/0008-5472.CAN-07-2354","article-title":"Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression","volume":"67","author":"Bunt","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0065","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1673-8527(09)60061-8","article-title":"Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis","volume":"37","author":"Ye","year":"2010","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.clim.2018.01.012_bb0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2012.02.008","article-title":"New insights into chronic inflammation-induced immunosuppression","volume":"22","author":"Kanterman","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.clim.2018.01.012_bb0075","first-page":"1021","article-title":"Myeloid-derived suppressor cells in malignant melanoma","volume":"12","author":"Umansky","year":"2014","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.clim.2018.01.012_bb0080","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0085","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12026-015-8734-1","article-title":"Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model","volume":"64","author":"Huang","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/cbr.2011.1116","article-title":"Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model","volume":"27","author":"Chen","year":"2012","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.clim.2018.01.012_bb0100","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/cncr.25537","article-title":"TNM seventh edition: what's new, what's changed: communication from the International Union against Cancer and the American Joint Committee on Cancer","volume":"116","author":"Sobin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clim.2018.01.012_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/5c756e7d-6e97-416f-836a-dced97cf46af","article-title":"Myeloid suppressor cell depletion augments antitumor activity in lung cancer","volume":"7","author":"Srivastava","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2018.01.012_bb0110","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3892\/ijo.2014.2378","article-title":"The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis","volume":"44","author":"Azuma","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.clim.2018.01.012_bb0115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/annonc\/mdl396","volume":"18","author":"Comella","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2018.01.012_bb0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1023\/A:1011160110205","article-title":"Cisplatin and vinorelbine in advanced and\/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen","volume":"12","author":"Gebbia","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2018.01.012_bb0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/sj.bjc.6601919","article-title":"Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK\/ERK activation","volume":"91","author":"Schweyer","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2018.01.012_bb0130","doi-asserted-by":"crossref","first-page":"19836","DOI":"10.3390\/ijms160819836","article-title":"Mitochondrial transcription factor a and mitochondrial genome as molecular targets for cisplatin-based cancer chemotherapy","volume":"16","author":"Kohno","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2018.01.012_bb0135","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2018.01.012_bb0140","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26663","article-title":"Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma","volume":"2","author":"Soriani","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2018.01.012_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2016.01.017","article-title":"Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals","volume":"373","author":"Shi","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.clim.2018.01.012_bb0150","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0155","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.01.012_bb0165","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","article-title":"CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis","volume":"24","author":"Katoh","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clim.2018.01.012_bb0170","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2018.01.012_bb0175","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.4049\/jimmunol.166.9.5398","article-title":"Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells","volume":"166","author":"Gabrilovich","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2018.01.012_bb0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2007-04-086835","article-title":"Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function","volume":"111","author":"Pan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clim.2018.01.012_bb0185","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1084\/jem.20050715","article-title":"Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma","volume":"202","author":"Rodriguez","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2018.01.012_bb0190","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00262-010-0855-8","article-title":"Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity","volume":"59","author":"Ostrand-Rosenberg","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2018.01.012_bb0195","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00262-016-1849-y","article-title":"Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy","volume":"65","author":"Baniyash","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2018.01.012_bb0200","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/jid.2012.444","article-title":"Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma","volume":"133","author":"Sevko","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2018.01.012_bb0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","article-title":"Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Weed","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0210","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.intimp.2009.03.015","article-title":"Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice","volume":"9","author":"Le","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2018.01.012_bb0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.oraloncology.2014.01.013","article-title":"Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer","volume":"50","author":"Tomihara","year":"2014","journal-title":"Oral Oncol."},{"key":"10.1016\/j.clim.2018.01.012_bb0220","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ijc.25702","article-title":"Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model","volume":"129","author":"Huang","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.clim.2018.01.012_bb0225","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","article-title":"Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes","volume":"74","author":"Kanterman","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0230","first-page":"1862","article-title":"XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells","volume":"61","author":"Asselin","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nm.2999","article-title":"Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth","volume":"19","author":"Bruchard","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2018.01.012_bb0240","first-page":"6166","article-title":"Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells","volume":"55","author":"Kondo","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2018.01.012_bb0245","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.drup.2005.06.004","article-title":"Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy","volume":"8","author":"Linder","year":"2005","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.clim.2018.01.012_bb0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/mco.2013.202","article-title":"A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress","volume":"2","author":"Xu","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.clim.2018.01.012_bb0255","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617304734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617304734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T18:34:31Z","timestamp":1529951671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617304734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":51,"alternative-id":["S1521661617304734"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.01.012","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}